Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Hjorth

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Novel thioamide derivatives as neutral CB1 receptor antagonistsJonas Boström, Roine I Olsson, Joakim Tholander, et al.
FEBS Letters|December 29, 2004
Identification and characterisation of a novel splice variant of the human CB1 receptorErik Ryberg, Huy Khang Vu, Niklas Larsson, et al.
JAMA Surgery|January 3, 2019
Reoperations After Bariatric Surgery in 26 Years of Follow-up of the Swedish Obese Subjects StudyStephan Hjorth, Ingmar Näslund, Johanna C Andersson-Assarsson, et al.
Biochemical and Biophysical Research Communications|May 19, 2004
Osteoporosis in MCHR1-deficient miceMohammad Bohlooly-Y, Margit Mahlapuu, Harriet Andersén, et al.
Pharmacology Research & Perspectives|August 4, 2015
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approachSarah K Walsh, Claire Y Hepburn, Oliver Keown, et al.
Neuropharmacology|March 21, 2015
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primatesStephan Hjorth, Cecilia Karlsson, Aurelija Jucaite, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2020
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson DiseaseSusanna Waters, Clas Sonesson, Peder Svensson, et al.
The Lancet. Diabetes & Endocrinology|February 27, 2017
Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects studyLena M S Carlsson, Kajsa Sjöholm, Cecilia Karlsson, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 17, 2024
Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosisTiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A Barrientos, et al.
Obesity (Silver Spring, Md.)|December 10, 2013
Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese miceAlicja A Skowronski, Michael V Morabito, Bridget R Mueller, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Novel thioamide derivatives as neutral CB1 receptor antagonistsJonas Boström, Roine I Olsson, Joakim Tholander, et al.
FEBS Letters|December 29, 2004
Identification and characterisation of a novel splice variant of the human CB1 receptorErik Ryberg, Huy Khang Vu, Niklas Larsson, et al.
JAMA Surgery|January 3, 2019
Reoperations After Bariatric Surgery in 26 Years of Follow-up of the Swedish Obese Subjects StudyStephan Hjorth, Ingmar Näslund, Johanna C Andersson-Assarsson, et al.
Biochemical and Biophysical Research Communications|May 19, 2004
Osteoporosis in MCHR1-deficient miceMohammad Bohlooly-Y, Margit Mahlapuu, Harriet Andersén, et al.
Pharmacology Research & Perspectives|August 4, 2015
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approachSarah K Walsh, Claire Y Hepburn, Oliver Keown, et al.
Neuropharmacology|March 21, 2015
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primatesStephan Hjorth, Cecilia Karlsson, Aurelija Jucaite, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2020
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson DiseaseSusanna Waters, Clas Sonesson, Peder Svensson, et al.
The Lancet. Diabetes & Endocrinology|February 27, 2017
Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects studyLena M S Carlsson, Kajsa Sjöholm, Cecilia Karlsson, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 17, 2024
Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosisTiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A Barrientos, et al.
Obesity (Silver Spring, Md.)|December 10, 2013
Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese miceAlicja A Skowronski, Michael V Morabito, Bridget R Mueller, et al.
Pageof 4